The Food and Drug Administration approved Juvmo (tavapadon) on September 28, 2026, clearing AbbVie’s once-daily pill as the first drug in a new pharmacological class for Parkinson’s disease: a selective agonist of the D1 and D5 dopamine receptors, rather than the D2/D3 receptors targeted by existing dopamine agonists such as pramipexole and ropinirole. AbbVie says the drug will reach U.S.…

Wellness

discover practical tips and motivation to start living a healthier lifestyle. embrace wellness with easy habits, inspiration, and guidance to begin your journey to better health today.

Women's

Diet and Weight Loss

Patient Stories

Senior